Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy

Laskar, Siddhartha; Kakoti, Sangeeta; Khanna, Nehal; Manjali, Jifmi Jose; Mangaj, Akshay; Puri, Ajay; Gulia, Ashish; Nayak, Prakash; Pai, Prathamesh; Nair, Deepa; Qureshi, Sajid; Chinnaswamy, Girish; Bajpai, Jyoti; Prabhash, Kumar; Rekhi, Bharat; Ramadwar, Mukta; Jambhekar, Nirmala A.; Janu, Amit; Juvekar, Sashikant; Purandare, Nilendu; Rangarajan, Venkatesh

doi:10.1016/j.radonc.2021.09.018

Cited by 7 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 18% of OS patients show signs of micrometastasis at the time of diagnosis, and the five-year survival rate of patients with stage III OS or higher stages of OS is very low (11)(12)(13). Moreover, the treatment outcomes are suboptimal because of the difficulty in early diagnosis, the early onset of metastasis, and high malignancy (14,15). The five-year survival of OS patients who do not receive chemotherapy is below 30%.…”

Section: Introductionmentioning

confidence: 99%

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma

Gao

2022

Front. Immunol.

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary bone cancer that is highly prevalent among adolescents and adults below the age of 20 years. The prognostic outcome of metastatic OS or relapse is extremely poor; thus, developing new diagnostic and therapeutic strategies for treating OS is necessary. Extracellular vesicles (EVs) ranging from 30–150 nm in diameter are commonly produced in different cells and are found in various types of body fluids. EVs are rich in biologically active components like proteins, lipids, and nucleic acids. They also strongly affect pathophysiological processes by modulating the intercellular signaling pathways and the exchange of biomolecules. Many studies have found that EVs influence the occurrence, development, and metastasis of osteosarcoma. The regulation of inflammatory communication pathways by EVs affects OS and other bone-related pathological conditions, such as osteoarthritis and rheumatoid arthritis. In this study, we reviewed the latest findings related to diagnosis, prognosis prediction, and the development of treatment strategies for OS from the perspective of EVs.

show abstract

Section: Introductionmentioning

confidence: 99%

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma

Gao

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Radionuclide scans can determine whether bone metastases occur in OS [7]. Frozen biopsies are used for rapid intraoperative diagnosis, and paraffin sections are used for obtaining accurate histological findings postoperatively [8]. High levels of serum alkaline phosphatase and lactate dehydrogenase are predictive of poor prognosis [9].…”

Section: Introductionmentioning

confidence: 99%

Functions and therapeutic potentials of exosomes in osteosarcoma

Yue

Chen

et al. 2022

Acta Materia Medica

View full text Add to dashboard Cite

Osteosarcoma, a primary malignant tumor of the skeleton, has a morbidity of 2.5 per 1 million people. The epiphysis of extremities is typically affected. Osteosarcoma has a high likelihood of early metastasis, rapid progression, and poor prognosis. The survival rate of patients with metastatic or recurrent osteosarcoma remains low; therefore, novel diagnostic and therapeutic methods are urgently needed. Exosomes, extracellular vesicles 30–150 nm in diameter, are secreted by various cells and are widely present in various body fluids. Exosomes are abundant in biologically active components, such as proteins, nucleic acids, and lipids. Exosomes participate in numerous physiological and pathological processes via intercellular substance exchange and signaling. This review presents the novel findings regarding exosomes in osteosarcoma diagnosis, prognosis, and therapeutics.

show abstract

“…Osteosarcoma (OS) is a severe kind of primary bone tumor that most often arises in young adults. 1,2 The progress in medicinal technology has allowed the use of surgical resection and different therapies including chemotherapy, these techniques not only broaden the treatment options for OS patients but also prolonged the 5-year survival rate by 70% 3 . But resistance to chemotherapy has become a major concern as it acts as an obstacle during treatment, hence, the success of therapy for OS may be greatly enhanced by addressing this issue of medication resistance.…”

Section: Introductionmentioning

confidence: 99%

Has_circ_0010220 regulates the miR-574-3p/IL-6 axis to increase doxorubicin resistance in osteosarcoma

Wang

Ran

2022

Hum Exp Toxicol

View full text Add to dashboard Cite

Background Osteosarcoma (OS) is the most common primary bone malignancy. It has an aggressive nature and produces drug resistance in diseased patients, which in turn causes obstacles in treating cancer with chemotherapy. The objective of our investigation was to analyze the function and hsa_circ_0010220 mechanism in doxorubicin (DOX) resistance to OS. Methods The hsa_circ_0010220, IL-6, and miR-574-3p levels in OS diseased tissues and cell resistance towards DOX drug were elucidated by qRT-PCR and Elisa assay. The DOX half-inhibitory concentration (IC50) was quantified by Cell Counting Kit-8. For this study, we used RNA pull-down, RNA immunoprecipitation, and a dual-luciferase reporter experiment to identify the proteins that interacted with has_circ_0010220, IL-6, and miR-574-3p in OS cells that have developed resistance towards DOX. Results The results indicated upregulated Hsa_circ_0010220 and IL-6 expression, However, DOX-resistant OS tissues and cells showed a downregulation of miR-574-3p. Reducing DOX resistance in vitro was achieved by silencing Has_circ_0010220. Further, by sponging miR-574-3p, increasing has_circ_0010220 boosted DOX resistance. However, miR-574-3p bound to IL-6 and inhibited DOX resistance. Additionally, it was discovered that hsa_circ_0010220 sponged miR-574-3p for upregulating IL-6 expression. Conclusions Hsa_circ_0010220 encouraged OS resistance to DOX by miR-574-3p/IL-6 axis regulation, suggesting its potency as a promising biomarker for treating OS.

show abstract

Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy

Cited by 7 publications

References 26 publications

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma

Functions and therapeutic potentials of exosomes in osteosarcoma

Has_circ_0010220 regulates the miR-574-3p/IL-6 axis to increase doxorubicin resistance in osteosarcoma

Contact Info

Product

Resources

About